BMAP-27
BMAP-27 is a cationic amphipathic α-helical antimicrobial peptide with anticancer activity. BMAP-27 disrupts the integrity and permeability of cell membranes, leading to the leakage of intracellular DNA, proteins and alkaline phosphatase. BMAP-27 increases intracellular ROS levels and reduces plasma endotoxin and TNF-α concentrations. BMAP-27 can be used in studies related to Salmonella infection, breast cancer, lung cancer and obstructive jaundice.
For research use only. We do not sell to patients.
- CAS No.: 184870-30-2
- Formula: C158H263N45O27
- Molecular Weight:3225.06
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
BMAP-27 (2-4 μM) potently inhibits the growth of S. aureus and E. coli with MIC values of 2-4 μM[2].
BMAP-27 (2-5 μM; 20-60 min) rapidly kills S. aureus and E. coli, achieving near-complete bacterial death within 20 min at its MIC of 2 μM[2].
BMAP-27 efficiently depolarises the cytoplasmic membranes of S. aureus and E. coli at concentrations lower than its MIC of 2-4 μM[2].
BMAP-27 (2 days) exhibits strong dose-dependent cytotoxicity against human MDA-361 and A549 cancer cells, with IC50 values lower than its haemolytic activity IC50[2].
BMAP-27 (1 h) exhibits moderate dose-dependent haemolytic activity against human red blood cells[2].
BMAP-27 (5-32 μM; 2-5 min) potently disrupts anionic POPC/POPG (2:1) membranes, shows moderate disruption of zwitterionic POPC/cholesterol (4:1) membranes at high concentrations, and exhibits Phosphatidylserine (PS) (HY-A0183)-dependent membrane disruption that correlates with its anticancer activity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male, 25-35 g, bile duct ligation surgery for obstructive jaundice model)[3]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced plasma endotoxin levels to 496.3 EU/mL at 2 hours post-LPS, 438.5 EU/mL at 6 hours, and 0.097 EU/mL at 24 hours in sham-operated mice.
Reduced plasma endotoxin levels to 553.1 EU/mL at 2 hours post-LPS, 553.1 EU/mL at 6 hours, and 0.283 EU/mL at 24 hours in BDL mice.
Reduced plasma TNF-α levels to 0.45 ng/mL at 2 hours post-LPS in sham-operated mice.
Reduced plasma TNF-α levels to 0.80 ng/mL at 2 hours post-LPS, 0.24 ng/mL at 6 hours, and 0.08 ng/mL at 24-48 hours in BDL mice.
Reduced plasma IL-6 levels to 76.3 pg/mL at 2 hours post-LPS, 199.5 pg/mL at 6 hours, 187.3 pg/mL at 24 hours, and 88.1 pg/mL at 48 hours in BDL mice.
Reduced lethality to 15% over 48 hours in BDL mice.
Reduced bacterial colonization in peritoneal fluid to a mean of 5.5 × 101 CFU/mL in BDL mice.
Reduced blood culture positivity to 10% in BDL mice.
Showed no drug-related adverse effects or physiological parameter changes in non-LPS-exposed mice.
Chemical Information
-
CAS No. 184870-30-2
-
Molecular Weight 3225.06
-
Formula C158H263N45O27
-
Sequence
Gly-Arg-Phe-Lys-Arg-Phe-Arg-Lys-Lys-Phe-Lys-Lys-Leu-Phe-Lys-Lys-Leu-Ser-Pro-Val-Ile-Pro-Leu-Leu-His-Leu-NH2
-
Sequence Shortening
GRFKRFRKKFKKLFKKLSPVIPLLHL-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Transepithelial/transendothelial electrical resistance assay
TEER measures electrical resistance across epithelial or endothelial monolayers cultured on permeable supports, and the readout reflects ionic conductance through the cell barrier, especially the paracellular pathway regulated by junctional integrity. TEER can be measured without destroying the monolayer and is commonly used before or during transport, permeability, barrier-disruption, and barrier-maturation experiments. TEER values are influenced by biological maturation and technical conditions; reported factors include temperature, medium formulation, passage number, electrode geometry, membrane properties, and junctional length during early monolayer maturation. Therefore, TEER should be interpreted with blank-insert subtraction, area normalization, repeated readings, and, when possible, orthogonal barrier readouts such as FITC-dextran flux or tight-junction staining.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
[1]. Xia R, et al. Insight into the inhibitory activity and mechanism of bovine cathelicidin BMAP 27 against Salmonella Typhimurium. Microbial pathogenesis. 2024 Feb;187:106540. [Content Brief]
[2]. Yang S, et al. Structural analysis and mode of action of BMAP-27, a cathelicidin-derived antimicrobial peptide. Peptides. 2019 Aug;118:170106. [Content Brief]
[3]. Ghiselli R, et al. Effects of the antimicrobial peptide BMAP-27 in a mouse model of obstructive jaundice stimulated by lipopolysaccharide. Peptides. 2006 Nov;27(11):2592-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)